Treatment of Idiopathic Multicentric Castleman Disease with Severe Multi-Organ Dysfunction (ECOG ≥ 2)
Idiopathic multicentric Castleman disease (iMCD) presenting with evidence of organ dysfunction is a clinically urgent scenario. When at least two severity criteria are met simultaneously, a structured, evidence-based response is required without delay.
Clinical Scenario
This protocol applies to patients with iMCD meeting at least 2 of the following severity criteria:
- ECOG performance status of 2 or greater
- Stage IV renal dysfunction — eGFR below 30 or serum creatinine above 3.0 mg/dL
- Anasarca, ascites, or pleural/pericardial effusion
- Hemoglobin of 8.0 g/dL or lower
- Pulmonary involvement or interstitial pneumonitis with dyspnea
These patients frequently present with critical multi-organ involvement — renal failure, severe anaemia, fluid overload, or impaired respiratory function — and often require intensive-level care.
Treatment Approach
The approach for this scenario calls for prompt initiation of high-dose corticosteroid therapy combined with a targeted biologic agent on an accelerated dosing schedule, with close daily clinical assessment during the first week of treatment.
An alternative biologic option is available if the primary agent cannot be obtained. The complete regimen — including the full drug sequence, response criteria, and escalation pathway — is contained in the structured protocol below.
Clinical Goals
Success is defined as a clear clinical and biochemical response within the first week, with measurable improvements in:
References
DOI: 10.1182/blood-2018-07-862334
Patients with severe iMCD have evidence of organ dysfunction such as renal failure, anasarca, severe anemia, and pulmonary dysfunction resulting in poor performance status likely requiring critical care.
Patients with severe iMCD must have at least 2 of the 5 criteria listed above.
These patients should be promptly started on a high-dose steroid regimen (eg, methylprednisolone 500 mg daily) together with siltuximab.
For pharmacokinetic reasons, an accelerated, weekly dosing schedule of siltuximab may be used for 1 month.
Severely ill patients should be treated with siltuximab and high-dose steroids, but if no clear response occurs within 1 week (or if status worsens at any time), then combination chemotherapy should be considered.
View source ↗